University Hospitals Cleveland Medical Center
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evolut™ EXPAND TAVR II Pivotal Trial | Constriction, Pathologic, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not applicable | 2026-09-30 | NCT05149755 | |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Recruiting | Phase 3 | 2026-09-29 | NCT06962800 | |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07205718 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06703073 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701682 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701669 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701656 | |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Recruiting | Phase 3 | 2026-05-13 | NCT05677971 | |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Recruiting | Phase 3 | 2026-03-05 | NCT06165341 | |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-10 | NCT05501886 |